149 related articles for article (PubMed ID: 30400002)
1. KLF14 potentiates oxidative adaptation via modulating HO-1 signaling in castrate-resistant prostate cancer.
Luo XH; Liu JZ; Wang B; Men QL; Ju YQ; Yin FY; Zheng C; Li W
Endocr Relat Cancer; 2019 Jan; 26(1):181-195. PubMed ID: 30400002
[TBL] [Abstract][Full Text] [Related]
2. Role of protein S in castration-resistant prostate cancer-like cells.
Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W
Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144
[TBL] [Abstract][Full Text] [Related]
3. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
Shen P; Sun J; Xu G; Zhang L; Yang Z; Xia S; Wang Y; Liu Y; Shi G
Prostate; 2014 Jun; 74(9):946-58. PubMed ID: 24737412
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
5. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
6. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus.
Hao JS; Zhu CJ; Yan BY; Yan CY; Ling R
Biomed Pharmacother; 2018 Mar; 99():859-866. PubMed ID: 29710485
[TBL] [Abstract][Full Text] [Related]
8. Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1.
Zhang Y; Chen B; Xu N; Xu P; Lin W; Liu C; Huang P
Int J Nanomedicine; 2021; 16():315-327. PubMed ID: 33469288
[TBL] [Abstract][Full Text] [Related]
9. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
10. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
11. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
12. Krüppel-like factor 14, a coronary artery disease associated transcription factor, inhibits endothelial inflammation via NF-κB signaling pathway.
Hu W; Lu H; Zhang J; Fan Y; Chang Z; Liang W; Wang H; Zhu T; Garcia-Barrio MT; Peng D; Chen YE; Guo Y
Atherosclerosis; 2018 Nov; 278():39-48. PubMed ID: 30248551
[TBL] [Abstract][Full Text] [Related]
13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
15. Heme Oxygenase 1 Impairs Glucocorticoid Receptor Activity in Prostate Cancer.
Leonardi DB; Anselmino N; Brandani JN; Jaworski FM; Páez AV; Mazaira G; Meiss RP; Nuñez M; Nemirovsky SI; Giudice J; Galigniana M; Pecci A; Gueron G; Vazquez E; Cotignola J
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30813528
[TBL] [Abstract][Full Text] [Related]
16. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
[TBL] [Abstract][Full Text] [Related]
18. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
20. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer.
Alaoui-Jamali MA; Bismar TA; Gupta A; Szarek WA; Su J; Song W; Xu Y; Xu B; Liu G; Vlahakis JZ; Roman G; Jiao J; Schipper HM
Cancer Res; 2009 Oct; 69(20):8017-24. PubMed ID: 19808972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
